# Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

> **NCT03179436** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 415 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** Quavonlimab
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Pembrolizumab/Quavonlimab

## Key facts

- **NCT ID:** NCT03179436
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-02
- **Primary completion:** 2024-04-08
- **Final completion:** 2024-04-08
- **Target enrollment:** 415 (ACTUAL)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03179436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03179436, "Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03179436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*